Radiopharm Theranostics (RADX) Debt to Equity (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Debt to Equity for 2 consecutive years, with $0.75 as the latest value for Q2 2025.
- Quarterly Debt to Equity fell 38.73% to $0.75 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $0.75 through Jun 2025, down 38.73% year-over-year, with the annual reading at $0.75 for FY2025, 38.73% down from the prior year.
- Debt to Equity for Q2 2025 was $0.75 at Radiopharm Theranostics, down from $1.22 in the prior quarter.
- The five-year high for Debt to Equity was $1.22 in Q2 2024, with the low at $0.75 in Q2 2025.